Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (ty
Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelin
Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had n
Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that p
Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with ine
US life expectancy is projected to stall at 80.4 years by 2050 while global ranking drops from 49th to 66th as obesity epidemic and drug mortality resurgence offset cardiovascular improvements
IHME's Global Burden of Disease 2050 forecast projects US life expectancy will reach only 80.4 years by 2050, up from 78.3 in 2022—a gain of just 2.1 years over 28 years. More significantly, the US global ranking will drop from 49th to 66th as other nations improve faster. This stall occurs despite
Loneliness independently increases all-cause dementia risk by 19-31% after adjusting for depression, with vascular dementia showing stronger association than Alzheimer's disease
This meta-analysis resolves the critical question of whether social isolation's dementia association operates independently of depression and cardiovascular disease. The unadjusted hazard ratio of 1.306 (95% CI 1.197-1.426) attenuates to 1.189 (95% CI 1.101-1.285) after controlling for both depressi
Adolescents aged 13-29 experience the highest loneliness rates globally at 17-24 percent exceeding elderly social isolation rates and challenging the assumption that loneliness is primarily an aging problem
The WHO Commission found that 17-21% of people aged 13-29 report feeling lonely, with female adolescents reaching 24.3% prevalence. This exceeds the elderly social isolation rate (up to 1 in 3 older adults, or ~33%, but this measures isolation not loneliness—a related but distinct construct). The fi
GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis
The within-class divergence between lixisenatide and exenatide in Parkinson's disease trials reveals that GLP-1 receptor agonist efficacy cannot be evaluated at the class level—drug-specific properties matter critically.
Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy
The WHO Commission on Social Connection's 3-year investigation found that loneliness and social isolation increase dementia risk by 50 percent. This effect operates independently of depression and cardiovascular disease pathways, establishing social disconnection as a direct neurological risk factor
GLP-1-induced anhedonia is dose-dependent and reverses within weeks of dose reduction through tonic dopamine suppression rather than permanent neurological change
Researchers compiling approximately 100 cases of GLP-1-induced anhedonia report that 'most cases appeared to resolve with dose reduction often as quickly as within a few weeks.' One specific case documented a patient on Zepbound (tirzepatide) who reduced from 15mg to 12.5mg weekly and 'within two we
Fewer than 10 percent of countries have transitioned to community-based mental health care despite evidence of superior outcomes and lower cost, indicating institutional care default persists through structural incentive lock-in not lack of evidence
The WHO Mental Health Atlas 2024 documents that fewer than 10 percent of countries have fully transitioned to community-based mental health care models, with most countries remaining in early stages of transition away from hospital/institutional care. This is striking because community-based care ha
Global mental health spending is frozen at 2 percent of health budgets despite 1 billion people affected, creating a 1,625x per-capita disparity between high-income and low-income countries that no other disease category approaches
The WHO Mental Health Atlas 2024 documents that mental health spending has remained frozen at 2 percent of global health budgets since 2017 — eight years without movement despite the WHO-Lancet Commission 2018, the COVID-19 mental health crisis 2020-2022, and the US Surgeon General's Loneliness Advi
Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability
The LIXIPARK Phase 2 trial demonstrated that lixisenatide (GLP-1 receptor agonist) met its primary endpoint in early Parkinson's disease patients (<3 years since diagnosis). At 12 months, the placebo group showed disease progression with MDS-UPDRS Part III motor scores worsening by +3.04 points, whi
AI productivity gains concentrate in high-skill workers while chronic disease burdens fall on lower-skill populations creating non-overlapping distributions that prevent AI from compensating for health-driven productivity losses
NBER Working Paper 34836 surveyed 6,000 executives across US, UK, German, and Australian firms and found that 80% of companies report NO productivity gains from AI despite widespread adoption (69% of firms actively use AI). Where gains DO occur, they concentrate in high-skill services and finance (~
GLP-1 neuroprotective effects in Parkinson's disease require regional CNS penetrance to the substantia nigra, not just blood-brain barrier crossing
Holscher's 2024 review proposed that GLP-1 agonists' neuroprotective effects correlate with blood-brain barrier penetrance, ranking drugs by BBB crossing ability. Exenatide and lixisenatide showed good BBB penetrance and positive Phase 2 results in Parkinson's disease, while liraglutide (limited BBB
Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
The Washington Post reports that 'the drug has been studied in 54,000+ trial participants' yet 'anhedonia is NOT currently listed as adverse drug reaction or warning in any GLP-1 label.' Doctors interviewed state that 'reports of anhedonia are not widespread' despite researchers now compiling approx
GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
A comprehensive 38-study systematic review found that anhedonia data is 'ABSENT' from GLP-1 psychiatric literature despite being the most commonly reported psychiatric adverse effect in clinical practice. The review notes 'emotional blunting mentioned as potential adverse outcome but no incidence da
Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration
The EVOKE and EVOKE+ Phase 3 trials enrolled 3,800 patients with confirmed Alzheimer's pathology and mild symptomatic disease, randomized to oral semaglutide 14mg vs placebo for 104 weeks. Both trials showed NO DIFFERENCE in primary endpoint (CDR-SB change) or secondary endpoint (ADCS-ADL-MCI). Crit
GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification
GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric mon
GLP-1 metabolic monitoring protocol uses glucose-ketone ratio for therapeutic targeting
Dr. Bosworth developed a metabolic monitoring protocol for GLP-1 therapy using blood glucose divided by blood ketones (the 'Dr. Boz Ratio'). The ratio provides three operational zones: >80 indicates glucose metabolism dominance, 40-80 indicates moderate ketosis, and <40 indicates deeper therapeutic
GLP-1 biomarker improvement without clinical benefit demonstrates surrogate endpoint limitation in neurodegeneration trials
The EVOKE trials produced a striking disconnection: statistically significant 10% reduction in CSF p-tau181 at week 78, yet zero change in Clinical Dementia Rating Sum of Boxes (CDR-SB) or Activities of Daily Living (ADCS-ADL-MCI) at week 104. Trial experts agreed the biomarker magnitude was insuffi
GLP-1 metabolic screening for schizophrenia patients uses 5.4% HbA1c threshold for early-stage risk targeting, below the 5.7% prediabetes cutoff
The Psychopharmacology Institute's Q1 2026 guidance establishes a 5.4% HbA1c screening threshold for initiating GLP-1 consideration in schizophrenia patients on clozapine or olanzapine. This threshold is 0.3 percentage points below the standard 5.7% prediabetes cutoff, positioning GLP-1 as a prevent
GLP-1 psychotropic co-medication quadruples suicidal ideation risk through pharmacodynamic interaction
Pharmacovigilance analysis within a 38-study systematic review found elevated suicidal ideation odds ratios of 4.45 for patients concurrently using GLP-1 receptor agonists with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a 4-fold increase in suicidal ideation risk
GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide
Dr. Bosworth and Dr. Albright report no emotional blunting in approximately 100-patient cohorts using low-dose tirzepatide at 0.6mg weekly — one-quarter the standard 2.5mg starting dose — paired with ketogenic diet. The protocol includes structured resistance training and adequate protein intake (1.
Page 2 of 13